Historical Valuation
Opus Genetics Inc (IRD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.24 is considered Undervalued compared with the five-year average of -2.15. The fair price of Opus Genetics Inc (IRD) is between 346.74 to 347.67 according to relative valuation methord. Compared to the current price of 2.00 USD , Opus Genetics Inc is Undervalued By 99.42%.
Relative Value
Fair Zone
346.74-347.67
Current Price：2.00
99.42%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Opus Genetics Inc (IRD) has a current Price-to-Book (P/B) ratio of 22.93. Compared to its 3-year average P/B ratio of 7.62 , the current P/B ratio is approximately 201.10% higher. Relative to its 5-year average P/B ratio of 7.62, the current P/B ratio is about 201.10% higher. Opus Genetics Inc (IRD) has a Forward Free Cash Flow (FCF) yield of approximately -22.47%. Compared to its 3-year average FCF yield of -35.14%, the current FCF yield is approximately -36.05% lower. Relative to its 5-year average FCF yield of -35.14% , the current FCF yield is about -36.05% lower.
P/B
Median3y
7.62
Median5y
7.62
FCF Yield
Median3y
-35.14
Median5y
-35.14
Competitors Valuation Multiple
AI Analysis for IRD
The average P/S ratio for IRD competitors is 7711.28, providing a benchmark for relative valuation. Opus Genetics Inc Corp (IRD.O) exhibits a P/S ratio of 10.24, which is -99.87% above the industry average. Given its robust revenue growth of -20.38%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IRD
1Y
3Y
5Y
Market capitalization of IRD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IRD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IRD currently overvalued or undervalued?
Opus Genetics Inc (IRD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.24 is considered Undervalued compared with the five-year average of -2.15. The fair price of Opus Genetics Inc (IRD) is between 346.74 to 347.67 according to relative valuation methord. Compared to the current price of 2.00 USD , Opus Genetics Inc is Undervalued By 99.42% .
What is Opus Genetics Inc (IRD) fair value?
IRD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Opus Genetics Inc (IRD) is between 346.74 to 347.67 according to relative valuation methord.
How does IRD's valuation metrics compare to the industry average?
The average P/S ratio for IRD's competitors is 7711.28, providing a benchmark for relative valuation. Opus Genetics Inc Corp (IRD) exhibits a P/S ratio of 10.24, which is -99.87% above the industry average. Given its robust revenue growth of -20.38%, this premium appears unsustainable.
What is the current P/B ratio for Opus Genetics Inc (IRD) as of Jan 10 2026?
As of Jan 10 2026, Opus Genetics Inc (IRD) has a P/B ratio of 22.93. This indicates that the market values IRD at 22.93 times its book value.
What is the current FCF Yield for Opus Genetics Inc (IRD) as of Jan 10 2026?
As of Jan 10 2026, Opus Genetics Inc (IRD) has a FCF Yield of -22.47%. This means that for every dollar of Opus Genetics Inc’s market capitalization, the company generates -22.47 cents in free cash flow.
What is the current Forward P/E ratio for Opus Genetics Inc (IRD) as of Jan 10 2026?
As of Jan 10 2026, Opus Genetics Inc (IRD) has a Forward P/E ratio of -4.73. This means the market is willing to pay $-4.73 for every dollar of Opus Genetics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Opus Genetics Inc (IRD) as of Jan 10 2026?
As of Jan 10 2026, Opus Genetics Inc (IRD) has a Forward P/S ratio of 10.24. This means the market is valuing IRD at $10.24 for every dollar of expected revenue over the next 12 months.